Search results for "TISSUE"

showing 10 items of 4413 documents

Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer.

2018

// Sonia Molina-Pinelo 1, 2 , Ana Salinas 1 , Nicolas Moreno-Mata 2 , Irene Ferrer 1, 2 , Rocio Suarez 1, 2 , Eduardo Andres-Leon 1 , Manuel Rodriguez-Paredes 4, 5 , Julian Gutekunst 4 , Eloisa Jantus-Lewintre 6, 7 , Carlos Camps 8, 9 , Amancio Carnero 1 , Luis Paz-Ares 1, 2 1 Instituto de Biomedicina de Sevilla (IBIS) (HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain 2 Medical Oncology Department, Hospital Universitario Doce de Octubre & Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spain 3 Thoracic Surgery Department, Hospital Universitario Virgen del Rocio, Sevilla, Spain 4 Division of Epigenetics, DKFZ-ZMBH Alliance, German Cancer Research Center, Heidelberg, Germany…

0301 basic medicineOncologymedicine.medical_specialtyPathology03 medical and health sciences0302 clinical medicineInternal medicineCancer genomeMedicineCOPDIn patienttranscriptional regulationLung cancerGenome stabilityThoracic surgery departmentbusiness.industryDLK1-DIO3 clustermedicine.diseaselung cancer030104 developmental biologyOncologyNormal lung030220 oncology & carcinogenesisDNA methylationbusinessLung tissueepigeneticResearch Paper
researchProduct

Current treatment options for HER2-positive breast cancer patients with brain metastases

2020

Abstract Brain metastases (BMs) are frequently associated with HER2+ breast cancer (BC). Their management is based on a multi-modal strategy including both local treatment and systemic therapy. Despite therapeutic advance, BMs still have an adverse impact on survival and quality of life and the development of effective systemic therapy to prevent and treat BMs from HER2 + BC represents an unmet clinical need. Trastuzumab-based therapy has long been the mainstay of systemic therapy and over the last two decades other HER2-targeted agents including lapatinib, pertuzumab and trastuzumab emtansine, have been introduced in the clinical practice. More recently, novel agents such as neratinib, tuc…

0301 basic medicineOncologymedicine.medical_specialtyPyridinesReceptor ErbB-2NeratinibTrastuzumab-emtansineBreast NeoplasmsLapatinibSystemic therapy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerQuality of lifeTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTrastuzumab deruxtecanHER2-positive breast cancerskin and connective tissue diseasesOxazolesneoplasmsTucatinibBrain Neoplasmsbusiness.industryBrain metastasesLapatinibHematologyTrastuzumabmedicine.disease030104 developmental biologyOncologychemistryTrastuzumab emtansine030220 oncology & carcinogenesisNeratinibQuality of LifeQuinazolinesPertuzumabbusinessmedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

2014

Abstract Background Trastuzumab emtansine (T-DM1), a new agent developed for the treatment of HER2-positive breast cancer, is an antibody-drug conjugate with a complex compound obtained by the conjugation of trastuzumab, a stable thioether linker, and the potent cytotoxic drug maytansine-derivate(DM1), which inhibits cell division and induces cell death. Field of study PubMed database, ESMO, ASCO, San Antonio Breast Cancer Symposium Meeting abstracts and clinicaltrials.gov were searched using the terms “Anti-HER2 treatment breast cancer and trastuzumab emtansine (T-DM1) “; papers considered relevant for the aim of this review were selected. Findings/results The phase I trials have determine…

0301 basic medicineOncologymedicine.medical_specialtyReceptor ErbB-2Antineoplastic AgentsBreast NeoplasmsAdo-Trastuzumab EmtansineAntibodies Monoclonal Humanized03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerTrastuzumabInternal medicineHumansMedicineMaytansineProgression-free survivalNeoplasm Metastasisskin and connective tissue diseasesTaxanebusiness.industryCancerHematologyTrastuzumabmedicine.diseaseMetastatic breast cancerClinical trial030104 developmental biologyClinical Trials Phase III as TopicOncologychemistryTrastuzumab emtansine030220 oncology & carcinogenesisDisease ProgressionFemaleNeoplasm Recurrence Localbusinessmedicine.drugCritical Reviews in Oncology/Hematology
researchProduct

BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients

2020

Background: Several available data suggest the association between specific molecular subtypes and BRCA1/2 mutational status. Previous investigations showed the association between BRCA1/2 pathogenic variants (PVs) in specific genomic regions and phenotypic variations of cancer relative risk, while the role of PV type and location in determining the breast cancer (BC) phenotypic features remains still unclear. The aim of this research was to describe the germline BRCA1/2 PVs in triple-negative breast cancer (TNBC) versus luminal-like BC and their potential leverage on BC phenotype. Patients & methods: We retrospectively collected and analyzed all clinical information of 531 patients wit…

0301 basic medicineOncologymedicine.medical_specialtygenetic testingGenotype phenotypeCorrelation03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerInternal medicinemedicineMutational statusskin and connective tissue diseasesTriple negativeTriple-negative breast cancerOriginal ResearchGenetic testinggermline pathogenic variantmedicine.diagnostic_testbusiness.industryBRCA1medicine.diseaseBRCA2030104 developmental biologyluminal-like breast cancerOncology030220 oncology & carcinogenesisCohorttriple-negative breast cancergermline pathogenic variantsbusinessTherapeutic Advances in Medical Oncology
researchProduct

Consistency in biomarkers expression between matched tissue microarray cores from primary gallblader and ovarian cancers

2019

Introduction. Tissue microarray (TMA) technique has been widely used, especially in immunohistochemical assays of new prognostic and predictive markers. The main objections raised by its opponents are the small amount of sampled material and the associated risk of inadequate assessment of analysed expression, resulting from the potential heterogeneity of tumour tissue. Material and methods. This study evaluated the compatibility of biomarker expression in two independent tissue cores, 1.5 mm in diameter, obtained by TMA technique from patients with gallbladder cancer (ERb, cytoPgR, HER2, CTGF) and ovarian cancer (PTEN, BCL2, PIK3CA, IGF1R). Comparison of the expression of individual biomark…

0301 basic medicineOncologymedicine.medical_specialtytissue microarraysTissue microarraybusiness.industrybiomarkersCancerMalignancymedicine.diseasegallbladder cancerCTGF03 medical and health sciencesovarian cancer030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicinemedicineBiomarker (medicine)ImmunohistochemistryGallbladder cancerOvarian cancerbusinessOncology in Clinical Practice
researchProduct

Is Danggui Safe to be Taken by Breast Cancer Patients?-A Skepticism Finally Answered by Comprehensive Preclinical Evidence.

2019

Angelica sinensis (AS, Danggui) has long been regarded to stimulate breast cancer growth; hence, the use of AS in breast cancer patients remains a major concern for both patients and practitioners. Since safety studies of herbs would be unethical to carry out in patients, the present study aimed to investigate the potential unsafe effects of AS in a systematic pre-clinical approach. Human breast cancer cells, breast orthotopic tumor-bearing mouse models, as well as primary breast cancer cells from patients’ tumors were used to evaluate the effect of AS hot water extract on the progression of breast tumors and/or growth of breast cancer cells. We showed that AS is not that stimulatory in bre…

0301 basic medicineOncologysafetymedicine.medical_specialtyprimary breast cancer cellsmedicine.drug_classXenotransplantationmedicine.medical_treatmentTraditional Chinese medicine03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicinemedicinePharmacology (medical)skin and connective tissue diseasesOriginal ResearchPharmacologySafety studiesbusiness.industrylcsh:RM1-950Angelica sinensisChinese herbal medicinesmedicine.diseaselcsh:Therapeutics. Pharmacology030104 developmental biologyEstrogen030220 oncology & carcinogenesisCancer cellestrogenic herbsBreast cancer cellsPrimary breast cancerbusinessFrontiers in pharmacology
researchProduct

Consequences of organ choice in describing bacterial pathogen assemblages in a rodent population

2017

SUMMARYHigh-throughput sequencing technologies now allow for rapid cost-effective surveys of multiple pathogens in many host species including rodents, but it is currently unclear if the organ chosen for screening influences the number and identity of bacteria detected. We used 16S rRNA amplicon sequencing to identify bacterial pathogens in the heart, liver, lungs, kidneys and spleen of 13 water voles (Arvicola terrestris) collected in Franche-Comté, France. We asked if bacterial pathogen assemblages within organs are similar and if all five organs are necessary to detect all of the bacteria present in an individual animal. We identified 24 bacteria representing 17 genera; average bacterial…

0301 basic medicineOperational taxonomic unitMESH: Sequence Analysis DNAEpidemiologyMESH : PrevalenceMESH : Tissue DistributionRodent DiseasesRNA Ribosomal 16Sbacterial pathogensPrevalenceMESH : DNA BacterialTissue DistributionMESH: AnimalsPathogen[SDV.EE]Life Sciences [q-bio]/Ecology environmenteducation.field_of_studybiologyEcologyArvicolinaeMicrobiotaMESH : Rodent Diseases3. Good healthMESH: RNA Ribosomal 16SInfectious DiseasesArvicolinaeFrancerodent-borne pathogenDNA Bacterial030106 microbiologyPopulationShort ReportZoology[ SDV.EE ] Life Sciences [q-bio]/Ecology environment03 medical and health sciencesAnimalsMESH: MicrobiotaMESH : BacteriaMESH: Tissue DistributionArvicola terrestriseducationMESH : FranceMESH: Prevalence[ SDE.BE ] Environmental Sciences/Biodiversity and EcologyBacteriaHost (biology)tissue selectionBacteria PresentSequence Analysis DNAMESH: Arvicolinaebiology.organism_classificationMESH: DNA BacterialMESH: FranceMESH : ArvicolinaeMESH : RNA Ribosomal 16SMESH: BacteriaHigh-Throughput Sequencing030104 developmental biologyMESH : MicrobiotaSpecies richnessMESH: Rodent DiseasesMESH : Animals[SDE.BE]Environmental Sciences/Biodiversity and EcologyBacteriaMESH : Sequence Analysis DNA
researchProduct

How to make a tongue: Cellular and molecular regulation of muscle and connective tissue formation during mammalian tongue development

2018

IF 6.614 (2016); International audience; The vertebrate tongue is a complex muscular organ situated in the oral cavity and involved in multiple functions including mastication, taste sensation, articulation and the maintenance of oral health. Although the gross embryological contributions to tongue formation have been known for many years, it is only relatively recently that the molecular pathways regulating these processes have begun to be discovered. In particular, there is now evidence that the Hedgehog, TGF-Beta, Wnt and Notch signaling pathways all play an important role in mediating appropriate signaling interactions between the epithelial, cranial neural crest and mesodermal cell pop…

0301 basic medicineOrganogenesisHedgehog signaling[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiologyBifid tongueMesodermWnt03 medical and health sciences0302 clinical medicineCranial neural crestTongueTongueMacroglossiamedicineAnimalsHumansTGF-betaHedgehogMammalsAglossiaMusclesMyogenesisGene Expression Regulation DevelopmentalCell BiologyAnatomymedicine.disease030104 developmental biologymedicine.anatomical_structureCranial neural crestConnective TissueNeural CrestEmbryologyGross anatomymedicine.symptom030217 neurology & neurosurgerySignal TransductionDevelopmental BiologySeminars in Cell & Developmental Biology
researchProduct

Two-Week Aflibercept or Erlotinib Administration Does Not Induce Changes in Intestinal Morphology in Male Sprague–Dawley Rats But Aflibercept Affects…

2019

Gastrointestinal toxicity is a frequently observed adverse event during cancer treatment with traditional chemotherapeutics. Currently, traditional chemotherapeutics are often combined with targeted biologic agents. These biologics, however, possess a distinct toxicity profile, and they may also exacerbate the adverse effects of traditional chemotherapeutics. In this study, we aimed to characterize the gastrointestinal and metabolic changes after a 2-week treatment period with aflibercept, an antiangiogenic VEGFR decoy, and with erlotinib, a tyrosine-kinase inhibitor. Male rats were treated either with aflibercept or erlotinib for 2 weeks. During the 2-week treatment period, the animals in …

0301 basic medicineOriginal articleCancer ResearchBevacizumabANTITUMOR-ACTIVITYmedicine.medical_treatmentBEVACIZUMAB3122 CancersAdipose tissuePharmacologylcsh:RC254-282TOXICITY03 medical and health sciences0302 clinical medicinemedicineOXIDATIVE STRESSCOMBINATIONAdverse effectAfliberceptChemotherapyIntestinal permeabilitybusiness.industryCHEMOTHERAPYmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMETASTATIC COLORECTAL-CANCER1ST-LINE TREATMENT030104 developmental biologyOncology030220 oncology & carcinogenesisCELLSACIDToxicityErlotinibbusinessmedicine.drug
researchProduct

αB-crystallin response to a pro-oxidant non-cytotoxic environment in murine cardiac cells: An "in vitro" and "in vivo" study.

2020

The αB-crystallin (HSPB5) protein is modulated in response to a wide variety of stressors generated by multiple physio-pathological conditions, sustained by reactive oxygen species (ROS) production. In cardiac muscle tissue, this protein regulates various cellular processes, such as protein degradation, apoptosis and the stabilization of cytoskeletal elements. In this work, we studied the role of HSPB5 expression, activation and localization in HL-1 murine cardiomyocytes exposed to pro-oxidant and non-cytotoxic H2O2 concentration, as well as in cardiac tissue isolated from mice following an acute, non-damaging endurance exercise. Our results demonstrated that HSPB5 is the most abundant HSP …

0301 basic medicineOxidative eustressOxidative phosphorylationProtein degradationBiochemistry03 medical and health sciencesMice0302 clinical medicineIn vivoPhysiology (medical)medicineAnimalsCardiac musclePhosphorylationchemistry.chemical_classificationReactive oxygen speciesHSPB5ChemistryCardiac musclealpha-Crystallin B ChainHydrogen PeroxidePro-oxidantEndurance exerciseHSPA1ACell biology030104 developmental biologymedicine.anatomical_structureProteolysisCardiac muscle tissueReactive Oxygen SpeciesOxidation-Reduction030217 neurology & neurosurgeryFree radical biologymedicine
researchProduct